Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care
17 août 2023 08h05 HE
|
Processa Pharmaceuticals, Inc.
Interim analysis of Phase 1B data suggests Processa’s novel chemotherapy treatment could improve safety and efficacy in more patients by individualizing the dosing regimen for each patient HANOVER,...
Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
12 mai 2022 16h20 HE
|
Processa Pharmaceuticals, Inc.
Amended Next Generation Capecitabine study has restarted which will elucidate timelines for de novo formation of DPDExpanded efforts for enrollment in PCS499PCS12852 on target to complete enrollment...
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
26 janv. 2022 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet...
Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update
11 nov. 2021 16h05 HE
|
Processa Pharmaceuticals, Inc.
Clinical Drug Pipeline is Funded and Targeting Major Milestones mid-2022 HANOVER, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the...
Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
04 août 2021 08h30 HE
|
Processa Pharmaceuticals, Inc.
Processa’s Phase 1b open label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for...
Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
06 juil. 2021 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation...
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
25 mars 2021 16h06 HE
|
Processa Pharmaceuticals, Inc.
Clinical drug pipeline is funded and targeting major milestones in 2021 HANOVER, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"),...
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
17 févr. 2021 08h00 HE
|
Processa Pharmaceuticals, Inc.
Strengthened Financial Position Supports Execution Through 2023 HANOVER, MD., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a...
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
05 nov. 2020 09h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS
20 août 2020 09h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a licensing agreement with Yuhan Corporation, a South Korean...